Future studies should include larger sample sizes and incorporate protein‐level analysis using methods like immunohistochemistry and Western blotting to validate these findings and explore the clinical utility of TSPO as a biomarker in CRC. This evidence concerns the gene TSPO and colorectal carcinoma.